1
|
Mohaissen T, Proniewski B, Targosz-Korecka M, Bar A, Kij A, Bulat K, Wajda A, Blat A, Matyjaszczyk-Gwarda K, Grosicki M, Tworzydlo A, Sternak M, Wojnar-Lason K, Rodrigues-Diez R, Kubisiak A, Briones A, Marzec KM, Chlopicki S. Temporal relationship between systemic endothelial dysfunction and alterations in erythrocyte function in a murine model of chronic heart failure. Cardiovasc Res 2021; 118:2610-2624. [PMID: 34617995 PMCID: PMC9491865 DOI: 10.1093/cvr/cvab306] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Indexed: 12/25/2022] Open
Abstract
Aims Endothelial dysfunction (ED) and red blood cell distribution width (RDW) are both
prognostic factors in heart failure (HF), but the relationship between them is not
clear. In this study, we used a unique mouse model of chronic HF driven by
cardiomyocyte-specific overexpression of activated Gαq protein (Tgαq*44 mice) to
characterize the relationship between the development of peripheral ED and the
occurrence of structural nanomechanical and biochemical changes in red blood cells
(RBCs). Methods and results Systemic ED was detected in vivo in 8-month-old Tgαq*44 mice, as
evidenced by impaired acetylcholine-induced vasodilation in the aorta and increased
endothelial permeability in the brachiocephalic artery. ED in the aorta was associated
with impaired nitric oxide (NO) production in the aorta and diminished systemic NO
bioavailability. ED in the aorta was also characterized by increased superoxide and
eicosanoid production. In 4- to 6-month-old Tgαq*44 mice, RBC size and membrane
composition displayed alterations that did not result in significant changes in their
nanomechanical and functional properties. However, 8-month-old Tgαq*44 mice presented
greatly accentuated structural and size changes and increased RBC stiffness. In
12-month-old Tgαq*44 mice, the erythropathy was featured by severely altered RBC shape
and elasticity, increased RDW, impaired RBC deformability, and increased oxidative
stress (gluthatione (GSH)/glutathione disulfide (GSSG) ratio). Moreover, RBCs taken from
12-month-old Tgαq*44 mice, but not from 12-month-old FVB mice, coincubated with aortic
rings from FVB mice, induced impaired endothelium-dependent vasodilation and this effect
was partially reversed by an arginase inhibitor [2(S)-amino-6-boronohexanoic acid]. Conclusion In the Tgαq*44 murine model of HF, systemic ED accelerates erythropathy and,
conversely, erythropathy may contribute to ED. These results suggest that erythropathy
may be regarded as a marker and a mediator of systemic ED in HF. RBC arginase and
possibly other RBC-mediated mechanisms may represent novel therapeutic targets for
systemic ED in HF.
Collapse
Affiliation(s)
- Tasnim Mohaissen
- Jagiellonian Center for Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego St, Krakow, 30-348 Poland.,Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., Krakow, 30-688 Poland
| | - Bartosz Proniewski
- Jagiellonian Center for Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego St, Krakow, 30-348 Poland
| | - Marta Targosz-Korecka
- Faculty of Physics, Institute of Astronomy and Applied Computer Science, Jagiellonian University Medical College, 11 Lojasiewicza St., Krakow, 30-348 Poland
| | - Anna Bar
- Jagiellonian Center for Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego St, Krakow, 30-348 Poland
| | - Agnieszka Kij
- Jagiellonian Center for Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego St, Krakow, 30-348 Poland
| | - Katarzyna Bulat
- Jagiellonian Center for Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego St, Krakow, 30-348 Poland
| | - Aleksandra Wajda
- Jagiellonian Center for Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego St, Krakow, 30-348 Poland.,Faculty of Chemistry, Jagiellonian University, 2Gronostajowa St, Krakow, 30-387 Poland
| | - Aneta Blat
- Jagiellonian Center for Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego St, Krakow, 30-348 Poland.,Faculty of Chemistry, Jagiellonian University, 2Gronostajowa St, Krakow, 30-387 Poland
| | - Karolina Matyjaszczyk-Gwarda
- Jagiellonian Center for Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego St, Krakow, 30-348 Poland.,Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., Krakow, 30-688 Poland
| | - Marek Grosicki
- Jagiellonian Center for Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego St, Krakow, 30-348 Poland
| | - Anna Tworzydlo
- Jagiellonian Center for Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego St, Krakow, 30-348 Poland
| | - Magdalena Sternak
- Jagiellonian Center for Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego St, Krakow, 30-348 Poland
| | - Kamila Wojnar-Lason
- Jagiellonian Center for Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego St, Krakow, 30-348 Poland.,Faculty of Medicine, Chair of Pharmacology, Jagiellonian University Medical College, 16 Grzegorzecka St, Krakow, 31-531 Poland
| | - Raquel Rodrigues-Diez
- Hospital La Paz Institute for Health Research IdiPAZ Department of Pharmacology, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, CV, Spain,; Ciber
| | - Agata Kubisiak
- Faculty of Physics, Institute of Astronomy and Applied Computer Science, Jagiellonian University Medical College, 11 Lojasiewicza St., Krakow, 30-348 Poland
| | - Ana Briones
- Hospital La Paz Institute for Health Research IdiPAZ Department of Pharmacology, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, CV, Spain,; Ciber
| | - Katarzyna M Marzec
- Jagiellonian Center for Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego St, Krakow, 30-348 Poland
| | - Stefan Chlopicki
- Jagiellonian Center for Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego St, Krakow, 30-348 Poland.,Faculty of Medicine, Chair of Pharmacology, Jagiellonian University Medical College, 16 Grzegorzecka St, Krakow, 31-531 Poland
| |
Collapse
|
2
|
Kij A, Bar A, Przyborowski K, Proniewski B, Mateuszuk L, Jasztal A, Kieronska-Rudek A, Marczyk B, Matyjaszczyk-Gwarda K, Tworzydlo A, Enggaard C, Hansen PBL, Jensen B, Walczak M, Chlopicki S. Thrombin Inhibition Prevents Endothelial Dysfunction and Reverses 20-HETE Overproduction without Affecting Blood Pressure in Angiotensin II-Induced Hypertension in Mice. Int J Mol Sci 2021; 22:ijms22168664. [PMID: 34445374 PMCID: PMC8395447 DOI: 10.3390/ijms22168664] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2021] [Revised: 08/05/2021] [Accepted: 08/07/2021] [Indexed: 02/02/2023] Open
Abstract
Angiotensin II (Ang II) induces hypertension and endothelial dysfunction, but the involvement of thrombin in these responses is not clear. Here, we assessed the effects of the inhibition of thrombin activity by dabigatran on Ang II-induced hypertension and endothelial dysfunction in mice with a particular focus on NO- and 20-HETE-dependent pathways. As expected, dabigatran administration significantly delayed thrombin generation (CAT assay) in Ang II-treated hypertensive mice, and interestingly, it prevented endothelial dysfunction development, but it did not affect elevated blood pressure nor excessive aortic wall thickening. Dabigatran’s effects on endothelial function in Ang II-treated mice were evidenced by improved NO-dependent relaxation in the aorta in response to acetylcholine in vivo (MRI measurements) and increased systemic NO bioavailability (NO2− quantification) with a concomitant increased ex vivo production of endothelium-derived NO (EPR analysis). Dabigatran treatment also contributed to the reduction in the endothelial expression of pro-inflammatory vWF and ICAM-1. Interestingly, the fall in systemic NO bioavailability in Ang II-treated mice was associated with increased 20-HETE concentration in plasma (UPLC-MS/MS analysis), which was normalised by dabigatran treatment. Taking together, the inhibition of thrombin activity in Ang II-induced hypertension in mice improves the NO-dependent function of vascular endothelium and normalises the 20-HETE-depedent pathway without affecting the blood pressure and vascular remodelling.
Collapse
Affiliation(s)
- Agnieszka Kij
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.); (A.B.); (K.P.); (B.P.); (L.M.); (A.J.); (A.K.-R.); (B.M.); (K.M.-G.); (A.T.); (M.W.)
| | - Anna Bar
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.); (A.B.); (K.P.); (B.P.); (L.M.); (A.J.); (A.K.-R.); (B.M.); (K.M.-G.); (A.T.); (M.W.)
| | - Kamil Przyborowski
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.); (A.B.); (K.P.); (B.P.); (L.M.); (A.J.); (A.K.-R.); (B.M.); (K.M.-G.); (A.T.); (M.W.)
| | - Bartosz Proniewski
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.); (A.B.); (K.P.); (B.P.); (L.M.); (A.J.); (A.K.-R.); (B.M.); (K.M.-G.); (A.T.); (M.W.)
| | - Lukasz Mateuszuk
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.); (A.B.); (K.P.); (B.P.); (L.M.); (A.J.); (A.K.-R.); (B.M.); (K.M.-G.); (A.T.); (M.W.)
| | - Agnieszka Jasztal
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.); (A.B.); (K.P.); (B.P.); (L.M.); (A.J.); (A.K.-R.); (B.M.); (K.M.-G.); (A.T.); (M.W.)
| | - Anna Kieronska-Rudek
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.); (A.B.); (K.P.); (B.P.); (L.M.); (A.J.); (A.K.-R.); (B.M.); (K.M.-G.); (A.T.); (M.W.)
| | - Brygida Marczyk
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.); (A.B.); (K.P.); (B.P.); (L.M.); (A.J.); (A.K.-R.); (B.M.); (K.M.-G.); (A.T.); (M.W.)
| | - Karolina Matyjaszczyk-Gwarda
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.); (A.B.); (K.P.); (B.P.); (L.M.); (A.J.); (A.K.-R.); (B.M.); (K.M.-G.); (A.T.); (M.W.)
| | - Anna Tworzydlo
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.); (A.B.); (K.P.); (B.P.); (L.M.); (A.J.); (A.K.-R.); (B.M.); (K.M.-G.); (A.T.); (M.W.)
| | - Camilla Enggaard
- Department of Cardiovascular and Renal Research, University of Southern Denmark, J.B. Winsløws Vej 21, 5000 Odense, Denmark; (C.E.); (P.B.L.H.); (B.J.)
| | - Pernille B. Lærkegaard Hansen
- Department of Cardiovascular and Renal Research, University of Southern Denmark, J.B. Winsløws Vej 21, 5000 Odense, Denmark; (C.E.); (P.B.L.H.); (B.J.)
| | - Boye Jensen
- Department of Cardiovascular and Renal Research, University of Southern Denmark, J.B. Winsløws Vej 21, 5000 Odense, Denmark; (C.E.); (P.B.L.H.); (B.J.)
| | - Maria Walczak
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.); (A.B.); (K.P.); (B.P.); (L.M.); (A.J.); (A.K.-R.); (B.M.); (K.M.-G.); (A.T.); (M.W.)
- Chair and Department of Toxicology, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland
| | - Stefan Chlopicki
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.); (A.B.); (K.P.); (B.P.); (L.M.); (A.J.); (A.K.-R.); (B.M.); (K.M.-G.); (A.T.); (M.W.)
- Chair of Pharmacology, Jagiellonian University Medical College, Grzegorzecka 16, 31-531 Krakow, Poland
- Correspondence:
| |
Collapse
|
3
|
Kieronska-Rudek A, Kij A, Kaczara P, Tworzydlo A, Napiorkowski M, Sidoryk K, Chlopicki S. Exogenous Vitamins K Exert Anti-Inflammatory Effects Dissociated from Their Role as Substrates for Synthesis of Endogenous MK-4 in Murine Macrophages Cell Line. Cells 2021; 10:1571. [PMID: 34206530 PMCID: PMC8303864 DOI: 10.3390/cells10071571] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 06/16/2021] [Accepted: 06/17/2021] [Indexed: 01/07/2023] Open
Abstract
Vitamins K exert a range of activities that extend far beyond coagulation and include anti-inflammatory effects, but the mechanisms involved in anti-inflammatory action remain unclear. In the present study, we showed that various forms of exogenous vitamins-K1, K3, K2 (MK-4, MK-5, MK-6 and MK-7)-regulated a wide scope of inflammatory pathways in murine macrophages in vitro, including NOS-2, COX-2, cytokines and MMPs. Moreover, we demonstrated for the first time that macrophages are able to synthesise endogenous MK-4 on their own. Vitamins with shorter isoprenoid chains-K1, K3 and MK-5-exhibited stronger anti-inflammatory potential than vitamins with longer isoprenoid chains (MK-6 and MK-7) and simultaneously were preferably used as a substrate for MK-4 endogenous production. Most interesting, atorvastatin pretreatment inhibited endogenous MK-4 production but had no impact on the anti-inflammatory activity of vitamins K. In summary, our results demonstrate that macrophages are able to synthesise endogenous MK-4 using exogenous vitamins K, and statin inhibits this process. However, the anti-inflammatory effect of exogenous vitamins K was independent of endogenous MK-4 synthesis.
Collapse
Affiliation(s)
- Anna Kieronska-Rudek
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.-R.); (A.K.); (P.K.); (A.T.)
- Department of Pharmacology, Medical College, Jagiellonian University, Grzegorzecka 16, 31-531 Krakow, Poland
| | - Agnieszka Kij
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.-R.); (A.K.); (P.K.); (A.T.)
| | - Patrycja Kaczara
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.-R.); (A.K.); (P.K.); (A.T.)
| | - Anna Tworzydlo
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.-R.); (A.K.); (P.K.); (A.T.)
| | - Marek Napiorkowski
- Chemistry Department, Pharmaceutical Research Institute, Rydygiera 8, 01-793 Warszawa, Poland; (M.N.); (K.S.)
| | - Katarzyna Sidoryk
- Chemistry Department, Pharmaceutical Research Institute, Rydygiera 8, 01-793 Warszawa, Poland; (M.N.); (K.S.)
| | - Stefan Chlopicki
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland; (A.K.-R.); (A.K.); (P.K.); (A.T.)
- Department of Pharmacology, Medical College, Jagiellonian University, Grzegorzecka 16, 31-531 Krakow, Poland
| |
Collapse
|